Follow-up of adult patients treated with growth hormone NUTROPIN Aq® (Nutropin in Adults)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/30183
• EU PAS number:
  EUPAS7944
• Study ID:
  30183
• Official title and acronym:
  Follow-up of adult patients treated with growth hormone NUTROPIN Aq® (Nutropin in Adults)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  The objectives of this observational study are: - Define the profile of patients treated with NutropinAq® and describe the conditions for initiation and follow-up of treatment - Assess the safety of NutropinAq® in adults - Collect data on the quality of life of adults treated with NutropinAq®.
• Study status:
  Finalised

Research institutions and networks

Institutions

Ipsen Pharma

Multiple centres: 55 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 01/02/2005

Actual: 01/02/2005

Study start date

Planned: 12/04/2005

Actual: 12/04/2005

Data analysis start date

Planned: 29/12/2009

Actual: 29/12/2009

Date of final study report

Planned: 30/06/2014

Actual: 07/07/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Ipsen Pharma

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable